Madrigal Pharmaceuticals
$499.40Change from previous close: −0.06%Absolute change: −$0.31
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 1,260 | 1,042 | 641 | 363 | — |
| Current assets | 1,246 | 1,033 | 637 | 361 | — |
| Cash and equivalents | 199 | 100 | 99.9 | 332 | — |
| Short-term investments | 785 | 826 | 534 | 27.2 | — |
| Receivables | 134 | 53.8 | 0.0 | — | — |
| Inventory | 74.8 | 34.1 | 0.0 | — | — |
| Net property, plant and equipment | 6.4 | 4.6 | 3.3 | 1.2 | — |
| Current liabilities | 310 | 169 | 119 | 116 | — |
| Accounts payable | 48.9 | 43.6 | 28.0 | 23.8 | — |
| Long-term debt | 340 | 118 | 115 | 49.3 | — |
| Total debt | 348 | 120 | 117 | 49.9 | — |
| Total liabilities | 657 | 288 | 235 | 165 | — |
| Total equity (incl. minority) | 603 | 754 | 405 | 197 | — |
| Retained earnings | -2,090 | -1,802 | -1,336 | -963 | — |